Glenmark Pharmaceuticals Shares Rallied 3.6 Percent Intraday

Glenmark Pharmaceuticals shares rallied 3.6 percent intraday after company received approval from US health regulator for anti-anginal drug.

The US Food and Drug Administration granted its approval for Ranolazine extended-release tablets, which will be available in 500 mg and 1,000 mg strengths.

Ranolazine is a generic version of Ranexa extended-release tablets of Gilead Sciences, Inc. The drug improves blood flow to help the heart work more efficiently.

For more information ✆ +91- 6232578593 or visit www.moneymarketmanthan.com